Document is current
Any future updates will be listed below
-
Authors
Galassi, Claudia
Manic, Gwenola
Esteller, Manel
Galluzzi, Lorenzo
Vitale, Ilio https://orcid.org/0000-0002-5918-1841
- License Information
-
More Information
Article History
Received: 10 April 2025
Revised: 26 June 2025
Accepted: 7 July 2025
First Online: 1 August 2025
Competing interests
: ME is/has been holding research contracts with Ferrer International and Incyte and receives personal fees from Quimatryx (outside the scope of this work). LG is/has been holding research contracts with Lytix Biopharma, Promontory, and Onxeo; has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation; and holds Promontory stock options. The other authors have no conflicts of interest to declare.
